|
⚲
|
| Keyboard |
| Boxer Capital Management LLC
✚
|
|
|---|---|
| CRD # | 330106 |
| SEC # | 801-130351 |
| CIK # | 0001465837, 0002018299 |
| AUM | 578.2 M (2026-05-11) |
| Employees | 19 (42% Investors, 0% Brokers) |
| Phone | 858-400-3115 |
| Address | 12860 El Camino Real, Ste 300 San Diego, CA 92130 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| BCTG Acquisition Corp | 0.2 | ||
| Kodiak Sciences Inc | 0.1 | ||
| Revolution Medicines Inc | 0.0 | ||
| Kymera Therapeutics Inc | 0.0 | ||
| Celcuity Inc | 0.0 | ||
| Consonance-HFW Acquisition Corp | 0.0 | ||
| Abivax Sa | 0.0 | ||
| Vaxcyte Inc | 0.0 | ||
| Nile Therapeutics Inc | 0.0 | ||
| Protagonist Therapeutics Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Boxer Capital Master Fund LP | [2025-03-31] | 60.2 M | 450.5 M |
| Filed 2025-10-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets $50,000,001 - $100,000,000 | ||||
| HF | Boxer Capital LLC | 2024-10-11 | 127.7 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 0.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 0.6 |
| By Discretionary | ||
| Discretionary | 4 | 0.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 0.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.1 | |
| United States Persons | 0.5 | |
| Total | 4 | 0.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Aaron Davis | Executive Officer | 40 | 4 | |
| Christopher Fuglesang | Executive Officer | 7 | 2 | |
| Boxer Capital GP LLC | Executive Officer | 2 | 2 | |
| Siddarth Subramony | Executive Officer | 1 | 1 | |
| Daniel Effinger | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001465837] | |
| 3 | [0001465837] | |
| 4 | [0001465837] | |
| SC 13D | [0001465837] | |
| SC 13G | [0001465837] | |
| 13F-HR | [0002018299] | |
| 3 | [0002018299] | |
| 4 | [0002018299] | |
| SC 13G | [0002018299] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $2.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 254900EDWZKUIJFQA680 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Tango Therapeutics Inc TNGX
Common Stock
|
2024-11-06 | Sell | 3,080,000 | $3.14 | 9,671,200 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2024-10-25 | Sell | 633,000 | $6.87 | 4,348,710 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2024-10-22 | Sell | 250,000 | $6.78 | 1,695,000 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2024-10-21 | Sell | 625,000 | $7.05 | 4,406,250 |
|
Tyra Biosciences Inc TYRA
Pre-Funded Warrant (right to purchase) · derivative
|
2024-10-18 | Grant | 2,000,000 | ||
|
Tyra Biosciences Inc TYRA
Common Stock
|
2024-10-18 | Disposed to issuer | 2,000,000 | ||
|
iTeos Therapeutics Inc ITOS
Common Stock
|
2024-05-10 | Grant | 1,142,857 | $17.50 | 19,999,998 |
|
Tyra Biosciences Inc TYRA
Common Stock
|
2024-02-06 | Grant | 63,412 | $13.01 | 824,990 |
|
Tyra Biosciences Inc TYRA
Warrant (right to purchase) · derivative
|
2024-02-06 | Grant | 705,280 | $13.01 | 9,175,693 |
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 203,754 | ||
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 3,135,966 | ||
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 3,201,440 | ||
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 30,518 | ||
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 287,866 | ||
|
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
|
2024-01-23 | Disposed to issuer | 332,809 | ||
|
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
|
2024-01-23 | Disposed to issuer | 3,578,036 | ||
|
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
|
2024-01-23 | Disposed to issuer | 1,413,475 | ||
|
Tango Therapeutics Inc TNGX
Common Stock
|
2023-10-16 | Buy | 500,000 | $6.84 | 3,420,000 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2023-10-13 | Buy | 750,000 | $7.07 | 5,302,500 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2023-10-09 | Sell | 50,000 | $9.91 | 495,500 |
| showing 20 of 194 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Tensor Edge Capital LLC
✚
|
MA | 584.8 M |
|
Praesidium Investment Management Company LLC
✚
|
NY | 582.9 M |
|
Freshford Capital Management LLC
✚
|
NY | 581.8 M |
|
Cello Capital Management LP
✚
|
NY | 577.2 M |
|
Tabor Asset Management LP
✚
|
NY | 577.2 M |
|
Birnam Oak Advisors LP
✚
|
NY | 577.0 M |
|
Muddy Waters Capital LLC
✚
|
TX | 576.3 M |
|
Western Standard LLC
✚
|
CA | 574.9 M |
|
Untitled Investments LP
✚
|
NY | 574.0 M |
|
Prevatt Capital Ltd
✚
|
571.5 M |